Apellis Aims New Pegcetacoplan Data At Market, Not Regulators

 
• By Alaric DeArment

The company said the user fee goal date for pegcetacoplan in geographic atrophy would move from November to February as it submitted longer-term data.

Apellis said it was submitting new, longer-term follow-up data to the FDA for its geographic atrophy drug • Source: Shutterstock

More from Sensory

More from Therapy Areas